Skip to content
Triangle logo TriangleGet started
← Study library

NCT00084682 · REGISTRY CONDITION SEARCH

Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2021-03-05

This phase II trial is studying how well FR901228 works in treating patients with unresectable recurrent or metastatic squamous cell carcinoma (cancer) of the head and neck. Drugs used in chemotherapy such as FR901228 work in different ways to stop tumor cells from dividing so they stop growing or die.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Disease Control (i.e., Achievement of Complete Response, Partial Response, or Stable Disease)

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Time to Progression

→

outcome · POSTED

Overall Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * histologically or cytologically confirmed squamous cell cancer of the head and neck (MedDRA code 90002024), excluding nasopharyngeal primaries, which is unresectable or metastatic; the disease must be incurable with surgery or radiation therapy; the tumor should preferably be present at the primary site, and it must be accessible to planned biopsy methods * Measurable disease by RECIST, * May have received any number of prior systemic chemotherapy regimen for unresectable, recurrent or metastatic disease; if the only site of measurable disease is a previously irradiated area, the patient must have documented progressive disease or biopsy-proven residual carcinoma; persistent disease after radiotherapy must be biopsy-proven at least 8 weeks after the completion of radiotherapy * Life expectancy of greater than 3 months * Normal organ and marrow function as defined by the following labs performed =\< 2 weeks of study entry: * Leukocytes ≥ 3,000/uL * Absolute Neutrophil Count ≥ 1,500/uL * Hemoglobin ≥ 10 gm% * Platelets ≥ 100,000/uL * Total Bilirubin =\< 1.5 X upper normal institutional limit * AST(SGOT)/ALT(SGPT) =\< 2.5 X upper normal institutional limits * Creatinine within normal institutional limits OR creatinine clearance ≥ 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal * PT/PTT =\< 1.1X upper normal institutional limits * Calcium within normal institutional limits * CPK, Troponin within normal institutional limits * Uric Acid within normal institutional limits * Ability to understand and the willingness to sign a written informed consent document; in addition to consent for the therapy, patients must give consent to required pre- and post-therapy blood and tissue samples; Exclusion Criteria: * Patients should not have had prior therapy with depsipeptide and may not be receiving any other investigational agents or drugs known to have histone deacetylase inhibitor activity such as sodium valproate * Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events * Significant cardiac disease including congestive heart failure that meets New York Heart Association (NYHA) class III and IV definitions (see Appendix II), history of myocardial infarction within one year of study entry, uncontrolled dysrhythmias, or poorly controlled angina * History of serious ventricular arrhythmia (VT or VF, \> 3 beats in a row), QTc \> 500 msec, or LVEF \< 40% * Patients may not be co-medicated with an agent that causes QTc prolongation; - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements * Not pregnant or lactating * History of HIV infection
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: romidepsin
    label
    Treatment (romidepsin)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (romidepsin)
    description
    Given IV
    name
    romidepsin
    other Names
    1. FK228
    2. FR901228
    3. Istodax
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
14
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Tumor response was assessed every eight weeks per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions as assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Stable disease (SD) was defined as having no evidence of response (CR or PR) as best response to therapy, and no evidence of disease progression (appearance of new lesions or \>/= 30% increase in target lesions) at 8 weeks.
    measure
    Disease Control (i.e., Achievement of Complete Response, Partial Response, or Stable Disease)
    time Frame
    Up to 2 years
secondary Outcomes
  1. measure
    Duration of Response
    time Frame
    Up to 2 years
  2. description
    All time to event endpoints will be evaluated using Kaplan Meier estimates and survival curves will be generated based on these estimates.
    measure
    Time to Progression
    time Frame
    Up to 2 years
  3. description
    All time to event endpoints will be evaluated using Kaplan Meier estimates and survival curves will be generated based on these estimates. One and two-year survival and median survival time (if attained) will be estimated and reported with 95% confidence limits. If the sample sizes are sufficient, subgroup analysis based on baseline factors will be performed using the log rank test to compare survival curves.
    measure
    Overall Survival
    time Frame
    Up to 2 years
Full study description
brief Summary
This phase II trial is studying how well FR901228 works in treating patients with unresectable recurrent or metastatic squamous cell carcinoma (cancer) of the head and neck. Drugs used in chemotherapy such as FR901228 work in different ways to stop tumor cells from dividing so they stop growing or die.
detailed Description
PRIMARY OBJECTIVES: I. To evaluate the rate of disease control (i.e., achievement of complete response, partial response, or stable disease) of the single agent depsipeptide in patients with unresectable recurrent or metastatic squamous cell carcinoma of the head and neck. SECONDARY OBJECTIVES: I. To evaluate the duration of response, time to progression, and overall survival for patients with incurable head and neck cancer treated with depsipeptide. TERTIARY OBJECTIVES: I. To determine the extent of histone hyperacetylation in peripheral blood mononuclear cells (PBMCs) as a readout of depsipeptide activity before and after depsipeptide administration, to correlate this activity with observed histone hyperacetylation in tumor and mucosal cells, and to correlate extent of depsipeptide activity with tumor response. II. To determine depsipeptide-induced changes in the gene expression profile of tumor cells from biopsies of accessible tumor tissue and of mucosal cells from transepithelial oral brush biopsies using cDNA microarrays containing 28,000 clones, and to correlate these changes with extent of histone hyperacetylation observed in PBMCs and tumor tissues. III. To determine depsipeptide-induced changes in methylation of candidate genes in tumor cells and oral mucosa epithelia. IV. To demonstrate altered expression of signaling and cell cycle-related proteins in tumor tissue in response to depsipeptide. OUTLINE: This is a multicenter study. Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years.
Source references
references
  1. citation
    Haigentz M Jr, Kim M, Sarta C, Lin J, Keresztes RS, Culliney B, Gaba AG, Smith RV, Shapiro GI, Chirieac LR, Mariadason JM, Belbin TJ, Greally JM, Wright JJ, Haddad RI. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol. 2012 Dec;48(12):1281-8. doi: 10.1016/j.oraloncology.2012.05.024. Epub 2012 Jun 28.
    pmid
    22748449
    type
    RESULT
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-5921e6c26c61891fc39a
      requested nct id
      NCT00084682
      primary nct id
      NCT00084682
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      payload sha256
      1c5eee3b32d69f05a8a57927a5c5709c56b54c76c000faa3b2d4c1dc6b538999
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-5921e6c26c61891fc39a
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00084682
      occurrences
      1. context exact
        NCT00084682
        end
        11
        exact text
        NCT00084682
        start
        0
      offset unit
      unicode_code_points
      query cond
      Laryngeal Cancer
      query disease state id
      ds-laryngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      source json pointer
      /studies/76/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      aa842af950c4fed7326cde1ee801e07bf5d047c5f137cc8af4002c9cba21ddef
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-9da3017b998c4d212649
      requested nct id
      NCT00084682
      primary nct id
      NCT00084682
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      payload sha256
      5314fc722cf834e70697d9db74fb59ea054c360acf1c8fa161a84cf153c1df35
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-9da3017b998c4d212649
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00084682
      occurrences
      1. context exact
        NCT00084682
        end
        11
        exact text
        NCT00084682
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hypopharyngeal Cancer
      query disease state id
      ds-hypopharyngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      source json pointer
      /studies/59/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      aa842af950c4fed7326cde1ee801e07bf5d047c5f137cc8af4002c9cba21ddef

    Preserved source evidence · Not medical advice